Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Tesamorelin + Ipamorelin Blend Dosage Protocol | PeptideDosages.com

Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend) Dosage Protocol Tesamorelin 5mg + Ipamorelin 5mg Dosage Chart Tesamorelin is dosed at 125 mcg–1 mg daily by subcutaneous injection in educational protocols, typically at night. A 10mg blend reconstituted with bacte

Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend) Dosage Protocol

Tesamorelin 5mg + Ipamorelin 5mg Dosage Chart

Tesamorelin is dosed at 125 mcg–1 mg daily by subcutaneous injection in educational protocols, typically at night. A 10mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water to the 10 mg vial → ~3.33 mg/mL total (1.67 mg/mL each peptide).

Typical daily range: 250–2000 mcg tesamorelin + 125–1000 mcg ipamorelin (gradual titration).

Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 16.7 mcg of each peptide on a U‑100 insulin syringe.

Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, use immediately or refrigerate and use within 24–48 hours[5].

This blend combines tesamorelin, a synthetic GHRH analog, with ipamorelin, a selective ghrelin mimetic (growth hormone secretagogue). When administered together, GHRH analogs and ghrelin mimetics produce synergistic GH pulses[1][2]. The FDA‑approved tesamorelin dose is 2 mg SC daily[3], while ipamorelin is commonly studied at 100–300 mcg SC daily[4]. This educational protocol presents a once‑daily subcutaneous approach with gradual titration using a 1:1 blend ratio.

Related research: For distinct compound, component, or formulation evidence and safety context, read Tesamorelin Peptide: Benefits, Uses, Side Effects, Dosage, and Research and Ipamorelin Peptide: Benefits, Uses, Side Effects, Dosage, and Research. These links are comparisons only; the compounds and formulations should not be treated as interchangeable.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)

Route: Subcutaneous (SC) | Frequency: Once daily

Weeks 1–2

250 mcg (0.25 mg)

125 mcg (0.125 mg)

23 units (0.23 mL)

Weeks 3–4

500 mcg (0.5 mg)

45 units (0.45 mL)

Weeks 5–6

1000 mcg (1.0 mg)

90 units (0.90 mL)

Weeks 7–10

1500 mcg (1.5 mg)

750 mcg (0.75 mg)

135 units (1.35 mL)

Weeks 11–16

2000 mcg (2.0 mg)

180 units (1.80 mL)

Note: The 1:1 blend ratio means tesamorelin and ipamorelin are present in equal amounts per mL. At 3.0 mL reconstitution: 1 mL = 1.67 mg tesamorelin + 1.67 mg ipamorelin. Higher‑volume injections (≥1.0 mL) may be split across two sites if preferred for comfort.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 24–48 hours[5].

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (Tesamorelin 5 mg + Ipamorelin 5 mg, 10 mg blend each):

8 weeks ≈ 10 vials

12 weeks ≈ 19 vials

16 weeks ≈ 31 vials

Insulin Syringes (U‑100):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (10 vials): 30 mL → 3 × 10 mL bottles

12 weeks (19 vials): 57 mL → 6 × 10 mL bottles

16 weeks (31 vials): 93 mL → 10 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

16 weeks: 224 swabs → recommend 3 × 100‑count boxes

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosage Miscalculation From Incorrect Vial Concentration Math

Peptide vials list total peptide mass (e.g., 5mg tesamorelin + 5mg ipamorelin per vial), but final concentration depends on the volume of bacteriostatic water used for reconstitution. Most dosage errors occur because users assume concentration matches a standard protocol without recalculating for their specific reconstitution volume. A 10mg total peptide vial reconstituted with 2mL bacteriostatic water yields 5mg/mL; the same vial reconstituted with 1mL yields 10mg/mL. Injecting 0.1mL of the first solution delivers 0.5mg total peptide; injecting 0.1mL of the second delivers 1mg. Double the dose. The calculation: divide total vial mass by reconstitution volume to determine mg/mL concentration. Then divide your target dose (in mg) by concentration (mg/mL) to calculate injection volume (in mL). Example: 5mg tesamorelin + 5mg ipamorelin vial, reconstituted with 2mL bacteriostatic water = 5mg/mL total peptide concentration. Target dose: 0.5mg total peptide per injection. 0.5mg ÷ 5mg/mL = 0.1mL injection volume. If you reconstituted with 1mL instead, the same 0.1mL injection would deliver 1mg. Twice the intended dose. Underdosing is more common than overdosing because most users default to 'standard' injection volumes (0.2mL, 0.25mL) without recalculating concentration. If your protocol calls for 0.3mg tesamorelin + 0.3mg ipamorelin per injection but your vial concentration is 2.5mg/mL, you need 0.24mL per injection. Not 0.2mL or 0.3mL. The 20% dosage error accumulates across week…
STORAGE

Storage and Handling: Temperature-Controlled Protocols That Preserve Peptide Integrity

Unreconstituted lyophilized tesamorelin and ipamorelin must be stored at −20°C (standard freezer temperature) until reconstitution. At this temperature, both peptides remain stable for 24–36 months from the synthesis date. Short-term ambient temperature exposure during shipping (up to 72 hours at 20–25°C) does not significantly degrade lyophilized peptides, but prolonged exposure above 25°C. Common in unrefrigerated mail delivery during summer. Causes measurable potency loss. If your peptide shipment arrives warm to the touch, contact the supplier immediately for potency verification or replacement. Once reconstituted with bacteriostatic water, both peptides must be refrigerated at 2–8°C and used within 28 days. The 28-day limit is not arbitrary. It reflects the degradation kinetics of the peptide-preservative system in aqueous solution. Beyond 28 days, benzyl alcohol's antimicrobial efficacy declines, and oxidative degradation of methionine and tryptophan residues in the peptide chains accelerates. Refrigerated reconstituted peptides that develop a yellowish tint, cloudiness, or any visible particulates have degraded and must be discarded. Travel requires planning: use an insulin cooler or medical-grade cold pack that maintains 2–8°C for 24–48 hours. Do not freeze reconstituted peptides. Ice crystal formation ruptures the tertiary protein structure, denaturing the peptide irreversibly. At Real Peptides, we've worked with research teams across temperature-sensitive peptide t…
02

Question drills

Open a question for its connected answer.

01What If I Run Out of Bacteriostatic Water Mid-Protocol?+

Use only USP-grade sterile water for injection as a temporary substitute. Administer the full reconstituted vial within 24 hours or discard unused solution. Tap water, distilled water, and saline introduce contamination or osmotic stress that denatures peptides. If bacteriostatic water is unavailable and you cannot complete administration within 24 hours, do not reconstitute the vial. Lyophilized powder remains stable at -20°C for months, while improperly reconstituted solution becomes useless within days.

SOURCE / realpeptides.co ↗
02What If Fluid Retention Develops During Titration?+

Reduce dose by 50% immediately and hold for one week. Peripheral oedema, morning hand stiffness, or new-onset carpal tunnel symptoms signal sodium retention exceeding renal clearance capacity. After one week off, resume at half the dose that triggered symptoms and extend titration by an additional four weeks. If oedema recurs at any dose, discontinue the protocol and assess for subclinical heart failure or renal impairment. Continuing therapy risks acute decompensation.

SOURCE / realpeptides.co ↗
03What If I Mix Injectable Tesamorelin + Ipamorelin Incorrectly — Does That Reduce Bioavailability?+

Yes, but the mechanism is different from oral degradation. Shaking the vial during reconstitution creates shear forces that denature peptide secondary structure, reducing receptor binding affinity even if the amino acid sequence remains intact. Similarly, injecting bacteriostatic water directly onto lyophilised powder (rather than down the vial side) causes localized turbulence that fragments peptides. Proper reconstitution technique. Slow injection, passive dissolution, no agitation. Preserves molecular structure and maintains the 70–85% bioavailability injectable peptides are known for.

SOURCE / realpeptides.co ↗
04What If I Want to Extend the Protocol Beyond 12 Weeks?+

Implement a 4-week washout period after 12 weeks of continuous 5/2 cycling before resuming. Extended protocols (16+ weeks without breaks) show diminishing visceral fat reduction after week 10–12 as receptor sensitivity declines. The washout allows GHRH and ghrelin receptors to upregulate, restoring responsiveness for subsequent cycles. Clinical trials using tesamorelin for HIV lipodystrophy demonstrate sustained efficacy with periodic washouts; continuous year-round administration without breaks is not supported by evidence.

SOURCE / realpeptides.co ↗
05What If I Want to Cycle Off After 16–20 weeks—Will Visceral Fat Return Immediately?+

Growth hormone receptor signaling returns to baseline within 48–72 hours of the last peptide injection, but the visceral fat you lost doesn't reaccumulate instantly. Adipocyte number remains stable—you're reducing the lipid content within existing visceral fat cells, not eliminating the cells themselves. If you return to the dietary and activity patterns that created the visceral fat accumulation originally, yes, it will return over 6–12 months. Maintaining the fat loss requires either continuing the protocol at a lower maintenance dose (tesamorelin 1mg 3–4x weekly, ipamorelin 200mcg daily) or implementing structured nutritional and training interventions that preserve the hormonal environment—adequate protein intake (1.6–2.0g/kg daily), resistance training 3–4x weekly to maintain growth hormone pulsatility, and avoiding chronic caloric surplus. The peptide protocol creates the metabolic opportunity; your behavior after cessation determines whether the results persist.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Tesamorelin/Ipamorelin Blend (Tesamorelin, Ipamorelin) Research References

It is a phase 3 compound Tesamorelin/Ipamorelin Blend (Tesamorelin, Ipamorelin) is a phase 3 compound Tesamorelin (Egrifta) approved for reduction of excess abdominal fat in HIV patients. n.d. Tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles. Ipamorelin selectively releases GH without affecting cortisol, prolactin, or ACTH. Combining GHRH and GHRP pathways produces synergistic GH release greater than either alone.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Tesamorelin + Ipamorelin Blend for Visceral Fat: Research Protocol Comparison

The table below compares the tesamorelin + ipamorelin blend for visceral fat against single-peptide protocols and conventional interventions based on published trial data and obse…

Comparison

Tesamorelin + Ipamorelin Blend: Protocol Comparison

Bedtime Protocol 30–60 min before sleep Maximizes nocturnal GH pulse amplitude and overnight lipolysis Last meal ≥3 hours pre-injection; breakfast delayed 60–90 min post-waking Us…